CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,724,648
- in 7 filings, $2.7M under 10b5-1 plans
Net −$2,724,648. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-13 | Bizily Scott Chief Legal Officer | Sale 10b5-1 | −1,635 | $12.00 | $20K | 8,617 |
| 2026-08-13 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,635 | 61,336 | ||
| 2026-08-04 | Kirn David See Remarks | Sale 10b5-1 | −26,842 | $10.23 | $275K | 844,895 |
| 2026-08-03 | Kirn David See Remarks | Sale 10b5-1 | −12,415 | $10.05 | $125K | 871,737 |
| 2026-07-10 | Kirn David See Remarks | Sale 10b5-1 | −15,283 | $12.01 | $184K | 884,594 |
| 2026-07-10 | Kirn David See Remarks | Sale 10b5-1 | −442 | $12.84 | $6K | 884,152 |
| 2026-07-09 | Kirn David See Remarks | Sale 10b5-1 | −42,608 | $12.87 | $548K | 899,877 |
| 2026-06-30 | Bizily Scott Chief Legal Officer | Option exercise 10b5-1 | +814 | $4.14 | $3K | 9,431 |
| 2026-06-30 | Bizily Scott Chief Legal Officer | Option exercise 10b5-1 | +5,752 | $6.49 | $37K | 15,183 |
| 2026-06-30 | Bizily Scott Chief Legal Officer | Sale 10b5-1 | −6,566 | $14.00 | $92K | 8,617 |
| 2026-06-30 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −814 | 62,971 | ||
| 2026-06-30 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,752 | 3,543 | ||
| 2026-06-23 | Bizily Scott Chief Legal Officer | Option exercise 10b5-1 | +9,810 | $4.14 | $41K | 18,427 |
| 2026-06-23 | Bizily Scott Chief Legal Officer | Sale 10b5-1 | −9,810 | $12.00 | $118K | 8,617 |
| 2026-06-23 | Bizily Scott Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,810 | 63,785 | ||
| 2026-06-22 | Kirn David See Remarks | Sale 10b5-1 | −114,746 | $10.47 | $1.2M | 942,485 |
| 2026-06-17 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-06-17 | THEUER CHARLES Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-06-17 | Miller-Rich Nancy Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2026-06-17 | GRAY SUSANNAH Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 |
Page 2 of 16 · 319 trades